Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer

British Journal of Cancer

Volumn 92, Issue 6, 2005, Pages 1019-1025

  Baur, M ^a,b   Schernhammer, E ^a,c   Gneist, M ^a   Sevelda, P ^d   Speiser, P ^e   Hudec, M ^a,e   Dittrich, Ch ^a,b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b 3rd Medical Department Oncology   (Austria)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d GENERAL HOSPITAL LINZ   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced ovarian cancer; Dose intensity; Etoposide; GM CSF; Platinum pretreatment; Salvage therapy

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONDANSETRON; PLATINUM; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GRAM NEGATIVE SEPSIS; GRANULOCYTOPENIA; HUMAN; MAXIMUM TOLERATED DOSE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; DISEASE COURSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVARY TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 17444420086     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602427     Document Type: Article

References (34)

1. Alici S, Saip P, Eralp Y, Aydiner A, Topuz E (2003) Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol 26: 358-362
2. Clark PI, Cottier B (1992) The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 19 (Suppl 14): 36-39
3. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, Reznek R, Masud T, Gregory W, Wrigley PF (1994) A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12: 1427-1435
4. De Wit R, van der Burg MEL, v.d. Gaast A, Logmans A, Stoter G, Verweij J (1994) Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 5: 656-657
5. Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Resell R (1999) Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer 85: 855-863
6. Garrow GC, Hainsworth JD, Johnson DH, Thomas M, Greco FA (1992) Prolonged administration of oral etoposide in previously-treated epithelial ovarian cancer: a phase II trial. Proc ASCO 11: 759
7. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322
8. Greco FA, Johnson DH, Hainsworth JD (1991) Chronic oral etoposide. Cancer 67: 303-309
9. Hainsworth JD, Johnson DH, Frazier SR, Greco FA (1989) Chronic daily administration of oral etoposide - a phase I trial. J Clin Oncol 7: 396-401
10. Hande KR, Krozely MG, Greco A, Hainsworth JD, Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11: 374-377
11. Hansen F, Malthe I, Krog H (1990) Phase II clinical trial of VP-16-213 (Etoposide) administered orally in advanced ovarian cancer. Gynecol Oncol 36: 369-370
12. Hillcoat BL, Campbell JJ, Pepperell R, Quinn MA, Bishop JF, Day A (1985) Phase II trial of VP 16-213 in advanced ovarian carcinoma. Gynecol Oncol 22: 162-166
13. Hoskins PJ, Swenerton KD (1994) Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12: 60-63
14. Kavanagh JJ, Tresukosol D, Gonzalez De Leon C, Edwards CL, Freedman RS, Hord M, Howell E, Lenzi R, Krakoff IH, Kudelka AP (1995) Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer 5: 351-354
15. Kimura K, Yamada K, Niitani H (1985) Phase I clinical study of NK 171 (etoposide). Gan To Kagaku Ryoho 12: 851-856
16. Kuhn W, Schmalfeldt B, Dose J, Pache L, Ulm K, Freitag K, Jänicke F, Graeff H (1996) Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Frührezidivs. Geburtsh Frauenheilk 56: 105-110
17. Lau ME, Hansen HH, Nissen NI, Pedersen H (1979) Phase I trial of a new form of an oral administration of VP-16-213. Cancer Treat Rep 63: 485-487
18. Markman M, Hakes T, Reichman B, Curtin J, Barakat R, Rubin S, Jones W, Lewis JL, Almadrones L, Hoskins W (1992) Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Clin Cancer Res 119: 55-57
19. Marzola M, Zucchetti M, Colombo N, Sessa C, Pagani O, D'Incalci M, Cavalli F, Mangioni C (1993) Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 4: 517-519
20. Maskens AP, Armand J-P, Lacave AJ, DeJager RL, Hansen HH, Wolff J-PM (1981) Phase II clinical trial of VP-16-213 in ovarian cancer. Cancer Treat Rep 65: 329-330
21. Nissen NI, Dombernowsky P, Hansen HH, Larsen V (1976) Phase I clinical trial of an oral solution of VP-16-213. Cancer Treat Rep 60: 943-945
22. Noda K, Fukuoka M, Komatsu H, Hayashihara K, Ariyoshi Y, Tanaka K, Nakajima H, Terashima Y, Nagao K, Furuse K et al (1994) Phase I clinical study of 21-consecutive-day oral administration of etoposide. Gan To Kagaku Ryoho 21: 1633-1639
23. Ogawa M, Ota K, Oyama A, Fukuoka M, Takada M, Yoshida S, San K, Rimura I, Ohnoshi T, Kuraishi Y et al. (1983) Phase I study of an oral administration of VP 16-213. Gan To Kagaku Ryoho 10: 2403-2407
24. Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L, Fiorentino M (1993) Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Cancer 72: 697-706
25. Rose PG, Blessing JA, Mayer AR, Homesley HD (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinomas: a Gynecologic Oncology Group Study. J Clin Oncol 16: 405-410
26. Salom E, Almeida Z, Mirhashemi R (2002) Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 14: 519-527
27. Seymour MT, Mansi JL, Gallagher CJ, Gore ME, Harper PG, Evans TRJ, Edmonds PM, Slevin ML (1994) Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 69: 191-195
28. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333-1340
29. Tuxen MK, Lund B, Hansen OP, Bertelsen K, Hansen M (1997) Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease. Int J Gynecol Cancer 7: 213-217
30. UICC (1987) Manual of adult and paediatric medical oncology. In Monfardini S, Brunner K, Crowther D, Eckhardt S, Olive D, Tanneberger S, Veronesi A, Whitehouse JMA, Wittes R (eds). Heidelberg: Springer
31. Weiss GR, Shaffer DW, DeMoor C, Rinaldi DA, Rodriguez GI, Eckardt JR, Stephens C, Von Hoff DD (1996) A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. Anti Cancer Drugs 7: 402-409
32. WHO (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO
33. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK (1989) Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor α and interferon in cancer patients. Blood 73: 643-646
34. Yasumizu T, Kato J (1995) Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus. J Obstet Gynecol 21: 569-576